BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25219563)

  • 1. Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).
    Klopfer SO; Stek JE; Petrecz M; Reisinger KS; Black SB; Goveia MG; Nicholson O; Gardner JL; Grosso AD; Brown ML; Kuter BJ; Schödel FP
    Vaccine; 2014 Dec; 32(52):7154-60. PubMed ID: 25219563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
    Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
    JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination.
    Schink T; Holstiege J; Kowalzik F; Zepp F; Garbe E
    Vaccine; 2014 Feb; 32(6):645-50. PubMed ID: 24374498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
    Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
    Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albumin.
    Rüger G; Gabutti G; Rümke H; Rombo L; Bernaola E; Diez-Domingo J; Martinon-Torres F; Høgh B; Konstantopoulos A; Fiquet A; Thomas S; Eymin C; Baudin M
    Pediatr Infect Dis J; 2012 Nov; 31(11):1166-72. PubMed ID: 22772170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.
    Yetman RJ; Shepard JS; Duke A; Stek JE; Petrecz M; Klopfer SO; Kuter BJ; Schödel FP; Lee AW
    Hum Vaccin Immunother; 2013 Aug; 9(8):1691-7. PubMed ID: 23744509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
    Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of measles-containing vaccines in 1-year-old children.
    Klein NP; Lewis E; Fireman B; Hambidge SJ; Naleway A; Nelson JC; Belongia EA; Yih WK; Nordin JD; Hechter RC; Weintraub E; Baxter R
    Pediatrics; 2015 Feb; 135(2):e321-9. PubMed ID: 25560438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.
    Committee on Infectious Diseases
    Pediatrics; 2011 Sep; 128(3):630-2. PubMed ID: 21873692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore: a phase II, randomized, double-blind trial.
    Huang LM; Lee BW; Chan PC; Povey M; Henry O
    Hum Vaccin Immunother; 2013 Jun; 9(6):1308-15. PubMed ID: 23425607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update: recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Mar; 57(10):258-60. PubMed ID: 18340332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: what do primary care physicians think?
    O'Leary ST; Suh CA; Marin M;
    Vaccine; 2012 Nov; 30(48):6731-3. PubMed ID: 22975026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.
    Klein NP; Fireman B; Yih WK; Lewis E; Kulldorff M; Ray P; Baxter R; Hambidge S; Nordin J; Naleway A; Belongia EA; Lieu T; Baggs J; Weintraub E;
    Pediatrics; 2010 Jul; 126(1):e1-8. PubMed ID: 20587679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.